Macrophage infiltration contributes to the instability of atherosclerotic plaques. In the present study, we investigated whether selective inhibition of PI3K/Akt/mTOR signaling pathway can enhance the stability of atherosclerotic plaques by activation of macrophage autophagy. In vitro study, selective inhibitors or siRNA of PI3K/Akt/mTOR pathways were used to treat the rabbit's peritoneal primary macrophage cells. Inflammation related cytokines secreted by macrophages were measured. Ultrastructure changes of macrophages were examined by transmission electron microscope. mRNA or protein expression levels of autophagy related gene Beclin 1, protein 1 light chain 3 II dots (LC3-II) or Atg5-Atg12 conjugation were assayed by quantitative RT-PCR or Western blot. In vivo study, vulnerable plaque models were established in 40 New Zealand White rabbits and then drugs or siRNA were given for 8 weeks to inhibit the PI3K/Akt/mTOR signaling pathway. Intravascular ultrasound (IVUS) was performed to observe the plaque imaging. The ultrastructure of the abdominal aortic atherosclerosis lesions were analyzed with histopathology. RT-PCR or Western blot methods were used to measure the expression levels of corresponding autophagy related molecules. We found that macrophage autophagy was induced in the presence of Akt inhibitor, mTOR inhibitor and mTOR-siRNA in vitro study, while PI3K inhibitor had the opposite role. In vivo study, we found that macrophage autophagy increased significantly and the rabbits had lower plaque rupture incidence, lower plaque burden and decreased vulnerability index in the inhibitors or siRNA treated groups. We made a conclusion that selective inhibition of the Akt/mTOR signal pathway can reduce macrophages and stabilize the vulnerable atherosclerotic plaques by promoting macrophage autophagy.
References
[1]
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, et al. (2009) Heart Disease and Stroke Statistics—2009 Update A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: 480–486. doi: 10.1161/circulationaha.108.191259
Libby P, Aikawa M (2002) Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8: 1257–1262. doi: 10.1038/nm1102-1257
[4]
Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, et al. (2007) Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 49: 706–715. doi: 10.1016/j.jacc.2006.09.047
[5]
Levine B, Kroemer G (2008) Autophagy in the pathogenesis of disease. Cell 132: 27–42. doi: 10.1016/j.cell.2007.12.018
Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, et al. (2008) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 129: 1500–1515. doi: 10.1038/jid.2008.379
[8]
Williams H, Johnson JL, Carson KG, Jackson CL (2002) Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 22: 788–792. doi: 10.1161/01.atv.0000014587.66321.b4
[9]
Chen WQ, Zhang L, Liu YF, Chen L, Ji XP, et al. (2007) Prediction of atherosclerotic plaque ruptures with high-frequency ultrasound imaging and serum inflammatory markers. Am J Physiol Heart Circ Physiol 293: H2836–H2844. doi: 10.1152/ajpheart.00472.2007
[10]
Zhong L, Chen WQ, Ji XP, Zhang M, Zhao YX, et al. (2008) Dominant-negative Mutation of Monocyte Chemoattractant Protein-1 Prevents Vulnerable Plaques from Rupture in Rabbits Independent of Serum Lipid Levels. J Cell Mol Med 12: 2362–2371. doi: 10.1111/j.1582-4934.2008.00261.x
[11]
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, et al. (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20–28. doi: 10.1056/nejmoa042378
[12]
Martinet W, De Meyer GR (2009) Autophagy in Atherosclerosis: A cell survival and death phenomenon with therapeutic potential. Circ Res 104: 304–317. doi: 10.1161/circresaha.108.188318
[13]
Meijer AJ, Codogno P (2006) Signaling and autophagy regulation in health and disease. Mol Aspects Med 27: 411–425. doi: 10.1016/j.mam.2006.08.002
[14]
Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T (2001) Beclin phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep 2: 330–335. doi: 10.1093/embo-reports/kve061
Colecchia D, Strambi A, Sanzone S, Iavarone C, Rossi M, et al. (2012) MAPK15/ERK8 stimulates autophagy by interacting with LC3 and GABARAP proteins. Autophagy 8: 1724–1740. doi: 10.4161/auto.21857
[17]
Klionsky DJ, Cuervo AM, Seglen PO (2007) Methods for Monitoring Autophagy from Yeast to Human. Autophagy 3: 181–206.
[18]
Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, et al. (2010) The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta 1803: 991–1002. doi: 10.1016/j.bbamcr.2010.04.005
[19]
Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, et al. (2007) Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 9: 1142–1151. doi: 10.1038/ncb1634
Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, et al. (2008) Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transpl 8: 1384–1392. doi: 10.1111/j.1600-6143.2008.02272.x
[22]
You Z, Al Kindi H, Abdul-Karim A, Barrette PO, Schwertani A (2013) Blocking the urotensin II receptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice. FASEB J 2..
[23]
Kang KH, Lemke G, Kim JW (2009) The PI3K-PTEN tug-of war, oxidative stress and retinal degeneration. Trends Mol Med 15: 191–198. doi: 10.1016/j.molmed.2009.03.005
[24]
Singh R, Cuervo AM (2012) Lipophagy: Connecting Autophagy and Lipid Metabolism. Int J Cell Biol 2012: 282041. doi: 10.1155/2012/282041
[25]
Mei S, Ni HM, Manley S, Bockus A, Kassel KM, et al. (2011) Differential Roles of Unsaturated and Saturated Fatty Acids on Autophagy and Apoptosis in Hepatocytes. J Pharmacol Exp Ther 339: 487–498. doi: 10.1124/jpet.111.184341
[26]
Jia G, Cheng G, Gangahar DM, Agrawal DK (2006) Insulin-like growth factor-1 and TNF-α regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells. Immunol Cell Biol 84: 448–454. doi: 10.1111/j.1440-1711.2006.01454.x
[27]
Chen WQ, Zhong L, Zhang L, Ji XP, Zhang M, et al. (2009) Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 156: 941–951. doi: 10.1111/j.1476-5381.2008.00102.x
[28]
Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, et al. (2004) Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119: 753–766. doi: 10.1016/j.cell.2004.11.038
O'Garra A, Murphy KM (2009) From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce TH1 development. Nat Immunol 10: 929–932. doi: 10.1038/ni0909-929
[31]
Park HJ, Lee SJ, Kim SH, Han J, Bae J, et al. (2011) IL-10 inhibits the starvation induced autophagy in macrophages via class I phosphatidylinositol 3-kinase (PI3K) pathway. Mol Immunol 48: 720–727. doi: 10.1016/j.molimm.2010.10.020
[32]
Guo JP, Coppola D, Cheng JQ (2011) IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 286: 37389–37398. doi: 10.1074/jbc.m111.287433
[33]
Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, et al. (2010) The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ 17: 1795–1804. doi: 10.1038/cdd.2010.63
[34]
Tenbaum SP, Ordó？ez-Morán P, Puig I, Chicote I, Arqués O, et al. (2012) β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 18: 892–901. doi: 10.1038/nm.2772
[35]
Li X, Prescott M, Adler B, Boyce JD, Devenish RJ (2013) Beclin 1 is required for starvation enhanced, but not rapamycin enhanced, LC3-associated phagocytosis of Burkholderia pseudomallei in RAW 264.7 cells. Infect Immun 81: 271–277. doi: 10.1128/iai.00834-12
[36]
Greenberger S, Yuan S, Walsh LA, Boscolo E, Kang KT, et al. (2011) Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 131: 2467–2476. doi: 10.1038/jid.2011.300
[37]
Huda R, Tüzün E, Christadoss P (2013) Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J Autoimmun 42: 94–104. doi: 10.1016/j.jaut.2013.01.003
